Sana biotechnology announces increased focus on type 1 diabetes and b-cell mediated autoimmune diseases with the potential to deliver clinical proof of concept data across multiple studies in 2024 and 2025

Prioritize clinical and preclinical development on type 1 diabetes (up421 and sc451), b-cell mediated autoimmune diseases (sc291), refractory b-cell malignancies (sc262), and the fusogen platform for generating in vivo car t cells
SANA Ratings Summary
SANA Quant Ranking